Trial: 202109063

A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma

Phase

II

Principal Investigator

Kahl, Brad

Disease Site

Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov